16+ Years Cancer-Free Thanks to Immunotherapy: Sharon Belvin's Melanoma Story
47.6 هزار بار بازدید -
2 سال پیش
-
Sharon Belvin was one of
Sharon Belvin was one of the first patients in the world treated with an immune checkpoint inhibitor--and remains cancer-free today. #Immune2Cancer #CIM22 #Melanoma #CancerSurvivor
In 2004, at only 22 years old, Sharon Belvin was diagnosed with stage 4 melanoma. Running out of options, her oncologist, Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center, informed her of a new type of cancer treatment called checkpoint blockade immunotherapy that was in early stages of testing. Without any hesitation, she enrolled in a clinical trial of ipilimumab (Yervoy), a CTLA-4 checkpoint inhibitor. After only four rounds of treatment, she was declared cancer-free one year later. Now, sixteen years later, she works as a health educator and wellness coach to help people with a variety of diseases return to full strength. https://www.cancerresearch.org/immuno...
This video is part of the 10th Annual Cancer Immunotherapy Month™ in June 2022, hosted by the Cancer Research Institute. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. https://www.cancerresearch.org/june
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
In 2004, at only 22 years old, Sharon Belvin was diagnosed with stage 4 melanoma. Running out of options, her oncologist, Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center, informed her of a new type of cancer treatment called checkpoint blockade immunotherapy that was in early stages of testing. Without any hesitation, she enrolled in a clinical trial of ipilimumab (Yervoy), a CTLA-4 checkpoint inhibitor. After only four rounds of treatment, she was declared cancer-free one year later. Now, sixteen years later, she works as a health educator and wellness coach to help people with a variety of diseases return to full strength. https://www.cancerresearch.org/immuno...
This video is part of the 10th Annual Cancer Immunotherapy Month™ in June 2022, hosted by the Cancer Research Institute. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. https://www.cancerresearch.org/june
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
2 سال پیش
در تاریخ 1401/03/13 منتشر شده
است.
47,609
بـار بازدید شده